Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation.

Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113:411–416. 5 Gaudy-Marqueste C, Carron R, Delsanti C, Loundou A, Monestier S, Archier E, et al. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 2014; 25:2086–2091. 6 Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 2015; 122:121–126. 7 Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, Shrieve DC. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg 2015; 123:395–401. 8 Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ, et al. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 2016; 26:387–394. 9 Xu Z, Lee CC, Ramesh A, Mueller AC, Schlesinger D, Cohen-Inbar O, et al. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. J Neurosurg 2017; 126:726–734. 10 Chowdhary M, Patel KR, Danish HH, Lawson DH, Khan MK. BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy. Onco Targets Ther 2016; 9:7149–7159. 11 Reyes V, Horrax G. Metastatic melanoma of the brain; report of a case with unusually long survival period following surgical removal. Ann Surg 1950; 131:237–242. 12 McCann WP, Weir BK, Elvidge AR. Long-term survival after removal of metastatic malignant melanoma of the brain. Report of two cases. J Neurosurg 1968; 28:483–487. 13 Hamid NA, Chandra A, Meyer CH. Multiple brain metastases from malignant melanoma with long-term survival. Br J Neurosurg 2004; 18:552–555. 14 Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 2011; 104:111–115. 15 Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994; 102:285–290. 16 Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135–2147. 17 COSMIC. COSMIC, Catalogue of Somatic Mutations In Cancer. Available at: http://cancer.sanger.ac.uk/cosmic/search?q=NRAS+ p.Q61R. [Accessed 15 January 2017]. 18 Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011; 24:666–672. 19 Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118:4014–4023. 20 Kong Y, Krauthammer M, Halaban R. Rare SF3B1 R625 mutations in cutaneous melanoma. Melanoma Res 2014; 24:332–334. 21 Kalirai H, Coupland SE. An update on ocular melanoma. Diagn Histopathol 2015; 21:19–25. 22 Santos GC, Zielenska M, Prasad M, Squire JA. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007; 60:1–7. 23 Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42:313–317. 24 Ehlers JP, Worley L, Onken MD, Harbour JW. Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res 2008; 14:115–122. 25 Namiki T, Yanagawa S, Izumo T, Ishikawa M, Tachibana T, Kawakami Y, et al. Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genet Cytogenet 2005; 157:1–11. 26 Rose AM, Cowen S, Jayasena C, Verity DH, Rose GE. Presentation, treatment and prognosis for secondary melanoma within the orbit. Front Oncol 2017; 7:125. Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation